Korean drugmakers challenge Glivec in generics fight

Korean pharmaceutical firms are gearing up to enter the 100 billion won leukemia drug market as the main patent of the market leader, Novartis’s Glivec (imatinib), is to expire on June 3, allowing for generic versions of the “miracle cancer drug.”

According to the Ministry of Food and Drug Safety (MFDS), a total of 30 generics produced have passed bioequivalence tests and are awaiting relea...